{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:23:54Z","timestamp":1787887434973,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010902","name":"Vanda Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010902","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.omtn.2025.102479","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T19:16:50Z","timestamp":1738696610000},"page":"102479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-0454","authenticated-orcid":false,"given":"Sandra","family":"Smieszek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartlomiej","family":"Przychodzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimeng","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Walker","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn","family":"Niccum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocky","family":"Brighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Aiken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos M.","family":"Polymeropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Birznieks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihael H.","family":"Polymeropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102479_bib2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ajhg.2014.10.002","article-title":"Truncating and Missense Mutations in IGHMBP2 Cause Charcot-Marie Tooth Disease type 2","volume":"95","author":"Cottenie","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102479_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.23838\/pfm.2018.00163","article-title":"Clinical and Genetic Aspects of Charcot-Marie-Tooth Disease Subtypes","volume":"3","author":"Nam","year":"2019","journal-title":"Precis. Future Med."},{"key":"10.1016\/j.omtn.2025.102479_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.676","article-title":"Whole Genome Sequencing Reveals Novel IGHMBP2 Variant Leading to Unique Cryptic Splice-Site and Charcot-Marie-Tooth Phenotype with Early Onset Symptoms","volume":"7","author":"Cassini","year":"2019","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.omtn.2025.102479_bib5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jns.12543","article-title":"Charcot\u2013Marie\u2013Tooth Neuropathies: Current Gene Therapy Advances and the Route toward Translation","volume":"28","author":"Stavrou","year":"2023","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"key":"10.1016\/j.omtn.2025.102479_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ajhg.2016.12.003","article-title":"Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease","volume":"100","author":"Carss","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102479_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113802","article-title":"RNA Helicase IGHMBP2 Regulates THO Complex to Ensure Cellular MRNA Homeostasis","volume":"43","author":"Prusty","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2025.102479_bib8","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/hmg\/ddp028","article-title":"IGHMBP2 Is a Ribosome-Associated Helicase Inactive in the Neuromuscular Disorder Distal SMA Type 1 (DSMA1)","volume":"18","author":"Guenther","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102479_bib9","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.nmd.2021.08.001","article-title":"Models for IGHMBP2-Associated Diseases: An Overview and a Roadmap for the Future","volume":"1","author":"Rzepnikowska","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2025.102479_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ng703","article-title":"Mutations in the Gene Encoding Immunoglobulin \u03bc-Binding Protein 2 Cause Spinal Muscular Atrophy with Respiratory Distress Type 1","volume":"29","author":"Grohmann","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102479_bib11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.nmd.2018.08.010","article-title":"IGHMBP2 Mutation Associated with Organ-Specific Autonomic Dysfunction","volume":"28","author":"Tomaselli","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2025.102479_bib13","series-title":"Antisense Technology: A Review. Journal of Biological Chemistry","author":"Crooke","year":"2021"},{"key":"10.1016\/j.omtn.2025.102479_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen Treatment of Spinal Muscular Atrophy: Current Knowledge and Existing Gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.omtn.2025.102479_bib15","article-title":"A Human-Based Functional NMJ System for Personalized ALS Modeling and Drug Testing","volume":"3","author":"Guo","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.omtn.2025.102479_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121752","article-title":"ALS Mutations in Both Human Skeletal Muscle and Motoneurons Differentially Affects Neuromuscular Junction Integrity and Function","volume":"289","author":"Badu-Mensah","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2025.102479_bib17","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1093\/nar\/gkac630","article-title":"Intratracheally Administered LNA Gapmer Antisense Oligonucleotides Induce Robust Gene Silencing in Mouse Lung Fibroblasts","volume":"50","author":"Shin","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102479_bib18","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The Genotype-Tissue Expression (GTEx) Project","author":"Lonsdale","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102479_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/nat.2021.0071","article-title":"Acute Neurotoxicity of Antisense Oligonucleotides after Intracerebroventricular Injection into Mouse Brain Can Be Predicted from Sequence Features","volume":"32","author":"Hagedorn","year":"2022","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2025.102479_bib20","first-page":"348","article-title":"Evaluation of Holistic Treatment for ALS Reveals Possible Mechanism and Therapeutic Potential","volume":"11","author":"Lavado","year":"2017","journal-title":"Int J Pharm Pharm Res"},{"key":"10.1016\/j.omtn.2025.102479_bib21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.expneurol.2014.10.005","article-title":"Axonal Charcot-Marie-Tooth Disease Patient-Derived Motor Neurons Demonstrate Disease-Specific Phenotypes Including Abnormal Electrophysiological Properties","volume":"263","author":"Saporta","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omtn.2025.102479_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biomaterials.2018.02.047","article-title":"Stem Cell Derived Phenotypic Human Neuromuscular Junction Model for Dose Response Evaluation of Therapeutics","volume":"166","author":"Santhanam","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2025.102479_bib23","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Supplementary Appendix for Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102479_bib24","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/brain\/awab226","article-title":"Induced Pluripotent Stem Cell-Derived Motorneurons of CMT Type 2 Patients Revealprogressive Mitochondrial Dysfunction","volume":"144","author":"Van Lent","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2025.102479_bib25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3390\/biology12060867","article-title":"In\u00a0Vitro Modeling as a Tool for Testing Therapeutics for Spinal Muscular Atrophy and IGHMBP2-Related Disorders","volume":"12","author":"Sierra-Delgado","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.omtn.2025.102479_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500078","article-title":"Gene Therapy Rescues Disease Phenotype in a Spinal Muscular Atrophy with Respiratory Distress Type 1 (SMARD1) Mouse Model","volume":"1","author":"Nizzardo","year":"2015","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102479_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.omtm.2021.07.008","article-title":"Defining the Optimal Dose and Therapeutic Window in SMA with Respiratory Distress Type I Model Mice, FVB\/NJ-Ighmpb2 Nmd-2J","volume":"23","author":"Shababi","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102479_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2023.04.017","article-title":"Presidential Symposium and Presentation of Top Abstracts","volume":"31","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102479_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/mt.2016.33","article-title":"Rescue of a Mouse Model of Spinal Muscular Atrophy with Respiratory Distress Type 1 by AAV9-IGHMBP2 Is Dose Dependent","volume":"24","author":"Shababi","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102479_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biotno.2024.01.001","article-title":"Organ-on-Chip Technology: Opportunities and Challenges","volume":"5","author":"Srivastava","year":"2024","journal-title":"Biotechnol. Notes"},{"key":"10.1016\/j.omtn.2025.102479_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101249","article-title":"Noncoding Variants Are a Rare Cause of Recessive Developmental Disorders in Trans with Coding Variants","volume":"26","author":"Lord","year":"2024","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtn.2025.102479_bib32","article-title":"Long-Read Motor Neuron RNAseq of Deep Intron 8 IGHMBP2 Variants Reveals Pathogenicity and Informs a Precision Therapeutic Strategy. Poster Board 8088W. Poster presented at: ASHG 2024 Annual Meeting. The American Society of Human Genetics","author":"Silverstein","year":"2024","journal-title":"Denver, CO, USA"},{"key":"10.1016\/j.omtn.2025.102479_bib33","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102479_bib34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nmeth.1591","article-title":"A More Efficient Method to Generate Integration-Free Human IPS Cells","volume":"8","author":"Okita","year":"2011","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtn.2025.102479_bib35","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1038\/ncomms4449","article-title":"High-Efficiency Motor Neuron Differentiation from Human Pluripotent Stem Cells and the Function of Islet-1","volume":"5","author":"Qu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102479_bib36","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/nprot.2016.110","article-title":"Generation of Human Muscle Fibers and Satellite-like Cells from Human Pluripotent Stem Cells in\u00a0Vitro","volume":"11","author":"Chal","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2025.102479_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/bioengineering7040133","article-title":"Characterization of Functional Human Skeletal Myotubes and Neuromuscular Junction Derived-from the Same Induced Pluripotent Stem Cell Source","volume":"7","author":"Guo","year":"2020","journal-title":"Bioengineering"},{"key":"10.1016\/j.omtn.2025.102479_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.745897","article-title":"A Functional Human-on-a-Chip Autoimmune Disease Model of Myasthenia Gravis for Development of Therapeutics","volume":"9","author":"Smith","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtn.2025.102479_bib39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/term.223","article-title":"Characterization of a Human Fetal Spinal Cord Stem Cell Line, NSI-566RSC, and Its Induction to Functional Motoneurons","volume":"4","author":"Guo","year":"2010","journal-title":"J.\u00a0Tissue Eng. Regen. Med."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125000332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125000332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:25:16Z","timestamp":1762601116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2162253125000332"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102479","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102479"}}